AGMB
AgomAb Therapeutics NV
8.70$
+1.5%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q4 24 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|
| – | -19.7% | -7.2% | +7.8% | +75.6% | |
| – | -23.5% | -8.9% | +9.7% | +94.3% | |
| – | -24.4% | -33.3% | +50.0% | +71.0% | |
| – | -24.4% | -10.1% | +11.2% | +94.4% | |
| – | – | – | -48.1% | – | |
| – | +0.0% | +0.0% | +0.0% | +0.0% | |
| – | +0.0% | +0.0% | +0.0% | +0.0% | |
| – | +2.3% | +21.9% | -18.0% | +36.6% | |
| – | +4.2% | +95.5% | -48.8% | +111.1% | |
| – | -11.4% | +2.9% | -2.8% | -5.4% | |
| – | +27.4% | +0.6% | -0.6% | +56.2% | |
| – | -21.9% | -10.9% | +12.2% | +80.6% | |
| – | – | – | – | – | |
| – | +17.2% | +14.7% | -25.6% | +35.9% |
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.